Xeris Biopharma Holdings (XERS) Revenue Growth (3y) (2023 - 2026)
Xeris Biopharma Holdings (XERS) Revenue Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 2.22% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 4.22% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -0.31% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 9.51% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.40% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 28.43% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 8.98% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.48 Bn | 1.36 Bn | 79.59 Mn | 34.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.32% |
| Mar 31, 2026 | 35.80% |
| Dec 31, 2025 | 37.31% |
| Sep 30, 2025 | 35.76% |
| Jun 30, 2025 | 41.40% |
| Mar 31, 2025 | 39.65% |
| Dec 31, 2024 | 41.02% |
| Sep 30, 2024 | 69.93% |
| Jun 30, 2024 | 75.41% |
| Mar 31, 2024 | 70.53% |
| Dec 31, 2023 | 84.61% |
| Sep 30, 2023 | 72.58% |